Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?

Novo Nordisk ADSes fell nearly 8% after CEO Mike Doustdar highlighted semaglutide's loss of exclusivity, with patents beginning to expire in December 2031. Obesity-care sales still rose 26% in 2025 to DKK82 billion ($12.6 billion), while second-quarter obesity drug sales grew 16% year over year. Management targets at least five multi-blockbuster launches by 2030, potentially generating more than DKK150 billion ($23 billion) in sales, and is considering M&A; however, execution risk and competition from Eli Lilly remain significant.

Analysis

The key valuation issue is not the 2031 patent date itself but whether Novo can defend its obesity franchise economics through the next 12-24 months. Payer formulary decisions, supply normalization, oral/injectable product sequencing, and the efficacy gap versus Lilly determine the earnings base from which the eventual loss-of-exclusivity cliff is discounted. A public five-blockbuster target should be treated as an aspiration rather than a forecast until Novo provides program-level probability-adjusted revenue, trial timelines, and capital-allocation detail.

LLY is the cleaner relative beneficiary: a sustained efficacy, access, or adherence advantage can translate into disproportionate share gains while both companies expand the category. Novo's cash balance alone is not a strategic edge in external M&A; scarce late-stage metabolic assets will be competitively bid, and an expensive acquisition could replace patent-cliff concern with return-on-invested-capital and integration risk. Smaller obesity-platform developers and contract manufacturing capacity providers could become indirect beneficiaries if Novo must accelerate business development or manufacturing partnerships.

The selloff may be directionally justified but temporally premature: a 2031 exclusivity event should not by itself reset near-term estimates unless it signals weaker confidence in the post-semaglutide pipeline. Over the next 1-3 months, the more consequential catalysts are prescription/share data, payer coverage changes, trial readouts, and any revision to 2027-28 obesity growth or gross-margin guidance. The structural bear case is falsified if Novo stabilizes U.S. share while demonstrating a credible next-generation product with differentiated efficacy or dosing and maintains operating leverage despite price pressure.

Key Decisions for Investors

• Maintain a 6-12 month relative-value position: long LLY / short NVO, sized beta-neutral. LLY has the stronger near-term share and execution setup, while NVO faces greater estimate and multiple risk; cover if NVO reports two consecutive quarters of U.S. obesity-share stabilization plus raised medium-term guidance.
• Do not add outright NVO solely on the patent-cliff selloff. Place a 1-3 month watch alert around the next earnings release: consider a tactical long only if prescription trends and 2027 obesity guidance hold, with downside defined by a guidance cut or evidence of accelerating gross-to-net price concessions.
• For existing NVO holders, use 6-9 month downside puts or put spreads rather than selling into headline volatility. The principal near-term risk is not 2031 generic entry but a de-rating triggered by weaker forward growth, lower obesity margins, or value-destructive M&A.
• Monitor obesity-focused biotech acquisition candidates only after Novo discloses transaction criteria and funding capacity. A premium bid for a late-stage asset would be a trading catalyst for targets but is not yet a basis to underwrite NVO upside; require clear revenue synergy and return thresholds.